FDA approves Telotristat Ethyl for carcinoid syndrome diarrhea

February 28, 2017 – The U.S. Food and Drug Administration today approved telotristat ethyl tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. Carcinoid syndrome is a cluster of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare, and often slow-growing. Most carcinoid tumors are found in the gastrointestinal … (leggi tutto)